Durect corporation announces additional safety data and efficacy signals from phase 1b clinical trial of dur-928 in nash patients at the liver meeting digital experience™ 2020

Cupertino, calif., nov. 13, 2020 /prnewswire/ -- durect corporation (nasdaq: drrx) today presented additional safety data and efficacy signals from its phase 1b clinical trial of dur-928 in nonalcoholic steatohepatitis (nash) patients in a poster presentation at the aasld liver meeting...
DRRX Ratings Summary
DRRX Quant Ranking